LncRNA AC116914.2 promotes the progression of oral cancer by targeting METTL3 via miR-1245a/ZNF250

lncRNA AC116914.2 通过 miR-1245a/ZNF250 靶向 METTL3 促进口腔癌的进展

阅读:2
作者:Chunyu Feng #,Xinyu Dou #,Xiaoshuai Xu,Zihan Dang,Zihan Jiang,Erhui Jiang,Zhengjun Shang

Abstract

Background: Aberrant long non-coding RNA (lncRNA) expression regulates tumor progression. With rising incidence, oral squamous cell carcinoma (OSCC) requires mechanistic study. LncRNA functions in OSCC remain unclear. Methods: Bioinformatics analysis was conducted to screen the highly expressed lncRNA AC116914.2 associated with m6A methylation in OSCC from The Cancer Genome Atlas database. Techniques including IHC, Western Blot, qPCR, cell functional assays, and in-vivo tumor formation were applied to assess the effects of AC116914.2 on OSCC malignant behaviors and fibroblast functions. Dual-luciferase assays explored the interactions among AC116914.2, miR-1245a, and ZNF250, while ChIP-qPCR verified ZNF250's regulatory effect on METTL3. Results: LncRNA AC116914.2 showed differential expression between tumor and normal tissues. Its knockdown significantly inhibited OSCC progression in vitro and in vivo. Mechanistically, AC116914.2 competitively bound to miR-1245a to maintain ZNF250 levels, stabilizing the oncogene METTL3 expression. Additionally, AC116914.2 promoted extracellular vesicle release and activated cancer-associated fibroblasts, fostering an OSCC-favorable microenvironment. Conclusion: This study shows that lncRNA AC116914.2, as a competing endogenous RNA (ceRNA), regulates the expression of METTL3 by competitively binding to miR-1245a with ZNF250, thus promoting OSCC progression. The discovery of this regulatory axis provides new diagnostic markers and therapeutic targets for OSCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。